254 related articles for article (PubMed ID: 19663128)
1. The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts.
Bilò MB; Severino M; Cilia M; Pio A; Casino G; Ferrarini E; Campodonico P; Milani M
Ann Allergy Asthma Immunol; 2009 Jul; 103(1):57-61. PubMed ID: 19663128
[TBL] [Abstract][Full Text] [Related]
2. Three days rush venom immunotherapy in bee allergy: safe, inexpensive and instantaneously effective.
Goldberg A; Yogev A; Confino-Cohen R
Int Arch Allergy Immunol; 2011; 156(1):90-8. PubMed ID: 21447964
[TBL] [Abstract][Full Text] [Related]
3. Immunoblot studies in allergic patients to hymenoptera venom before and during immunotherapy.
Pereira Santos MC; Pedro E; Spínola Santos A; Branco Ferreira M; Palma Carlos ML; Palma Carlos AG
Eur Ann Allergy Clin Immunol; 2005 Sep; 37(7):273-8. PubMed ID: 16285233
[TBL] [Abstract][Full Text] [Related]
4. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
Goldberg A; Confino-Cohen R
J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
[TBL] [Abstract][Full Text] [Related]
5. Purified vs. nonpurified venom immunotherapy.
Bilò MB; Antonicelli L; Bonifazi F
Curr Opin Allergy Clin Immunol; 2010 Aug; 10(4):330-6. PubMed ID: 20410817
[TBL] [Abstract][Full Text] [Related]
6. Safety of Ultrarush Venom Immunotherapy: Comparison Between Children and Adults.
Nittner-Marszalska M; Cichocka-Jarosz E; Małaczyńska T; Kraluk B; Rosiek-Biegus M; Kosinska M; Pawłowicz R; Lis G
J Investig Allergol Clin Immunol; 2016; 26(1):40-7. PubMed ID: 27012015
[TBL] [Abstract][Full Text] [Related]
7. Ultrarush venom desensitization after systemic reactions during conventional venom immunotherapy.
Oren E; Chegini S; Hamilos DL
Ann Allergy Asthma Immunol; 2006 Nov; 97(5):606-10. PubMed ID: 17165267
[TBL] [Abstract][Full Text] [Related]
8. Rush hymenoptera venom immunotherapy is efficacious and safe.
Pasaoglu G; Sin BA; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(4):232-8. PubMed ID: 16889280
[TBL] [Abstract][Full Text] [Related]
9. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
Ruëff F; Wenderoth A; Przybilla B
J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety.
Müller U; Helbling A; Berchtold E
J Allergy Clin Immunol; 1992 Feb; 89(2):529-35. PubMed ID: 1740583
[TBL] [Abstract][Full Text] [Related]
11. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis.
Verburg M; Oldhoff JM; Klemans RJ; Lahey-de Boer A; de Bruin-Weller MS; Röckmann H; Sanders C; Bruijnzeel-Koomen CA; Pasmans SG; Knulst AC
Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):192-6. PubMed ID: 26549336
[TBL] [Abstract][Full Text] [Related]
12. Adverse reactions to venom immunotherapy.
Ramirez DA; Londono S; Evans R
Ann Allergy; 1981 Dec; 47(6):435-9. PubMed ID: 7325415
[TBL] [Abstract][Full Text] [Related]
13. [Immunotherapy against hymenoptera venom: report of ten patients].
Guzmán M MA; Salinas L J; Toche P P; Marinovic M MA; Gallardo O AM
Rev Med Chil; 2007 Dec; 135(12):1566-71. PubMed ID: 18357358
[TBL] [Abstract][Full Text] [Related]
14. Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations.
Ruëff F; Wolf H; Schnitker J; Ring J; Przybilla B
Allergy; 2004 Jun; 59(6):589-95. PubMed ID: 15147443
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of venom immunotherapy.
Hafner T; DuBuske L; Kosnik M
Ann Allergy Asthma Immunol; 2008 Feb; 100(2):162-5. PubMed ID: 18320918
[TBL] [Abstract][Full Text] [Related]
16. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy.
Dugas-Breit S; Przybilla B; Dugas M; Arnold A; Pfundstein G; Küchenhoff H; Ruëff F
Clin Exp Allergy; 2010 Apr; 40(4):643-9. PubMed ID: 20100187
[TBL] [Abstract][Full Text] [Related]
17. Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.
Roll A; Hofbauer G; Ballmer-Weber BK; Schmid-Grendelmeier P
J Investig Allergol Clin Immunol; 2006; 16(2):79-85. PubMed ID: 16689180
[TBL] [Abstract][Full Text] [Related]
18. Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy.
Díez Gómez ML; Quirce Gancedo S; Juliá de Páramo B
Allergol Immunopathol (Madr); 1995; 23(6):277-84. PubMed ID: 8579006
[TBL] [Abstract][Full Text] [Related]
19. [Accelerated desensitization for hymenoptera venom allergy in 30 hours: efficacy and safety in 150 cases].
van der Brempt X; Ledent C; Mairesse M
Rev Med Brux; 1997 Jun; 18(3):120-4. PubMed ID: 9273600
[TBL] [Abstract][Full Text] [Related]
20. High sensitivity of basophils predicts side-effects in venom immunotherapy.
Kosnik M; Silar M; Bajrovic N; Music E; Korosec P
Allergy; 2005 Nov; 60(11):1401-6. PubMed ID: 16197472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
